Clinical Trial Update: A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease [Phase 2]

View source ↗

Summary

The Phase 2 study evaluating CC-5013 in adolescents and adults with moderately severe Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CC-5013 (lenalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED